JP2012502884A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012502884A5 JP2012502884A5 JP2011526360A JP2011526360A JP2012502884A5 JP 2012502884 A5 JP2012502884 A5 JP 2012502884A5 JP 2011526360 A JP2011526360 A JP 2011526360A JP 2011526360 A JP2011526360 A JP 2011526360A JP 2012502884 A5 JP2012502884 A5 JP 2012502884A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- compound
- pharmaceutically acceptable
- acceptable salt
- intervening substituent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 1,3-benzodioxol-4-ylmethyl Chemical group 0.000 claims description 98
- 150000001875 compounds Chemical class 0.000 claims description 67
- 125000001424 substituent group Chemical group 0.000 claims description 57
- 229910052739 hydrogen Inorganic materials 0.000 claims description 42
- 229910052799 carbon Inorganic materials 0.000 claims description 38
- 125000003342 alkenyl group Chemical group 0.000 claims description 32
- 125000000217 alkyl group Chemical group 0.000 claims description 32
- 125000000304 alkynyl group Chemical group 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 29
- 238000000034 method Methods 0.000 claims description 28
- 125000000392 cycloalkenyl group Chemical group 0.000 claims description 16
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 16
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 16
- 125000000547 substituted alkyl group Chemical group 0.000 claims description 14
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 12
- 101001120790 Caenorhabditis elegans UDP-N-acetylglucosamine-peptide N-acetylglucosaminyltransferase Proteins 0.000 claims description 11
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 10
- 206010020751 Hypersensitivity Diseases 0.000 claims description 10
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 8
- 201000004624 Dermatitis Diseases 0.000 claims description 8
- 208000026935 allergic disease Diseases 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 230000005764 inhibitory process Effects 0.000 claims description 7
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 6
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 6
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 6
- 206010012289 Dementia Diseases 0.000 claims description 6
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 6
- 208000029523 Interstitial Lung disease Diseases 0.000 claims description 6
- 206010028980 Neoplasm Diseases 0.000 claims description 6
- 208000034799 Tauopathies Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000001404 mediated effect Effects 0.000 claims description 6
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 6
- 208000027089 Parkinsonian disease Diseases 0.000 claims description 5
- 206010034010 Parkinsonism Diseases 0.000 claims description 5
- 230000002401 inhibitory effect Effects 0.000 claims description 5
- 229940002612 prodrug Drugs 0.000 claims description 5
- 239000000651 prodrug Substances 0.000 claims description 5
- MSRRUOTWMWVEQW-SYLRKERUSA-N (2r)-2-amino-n-[[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]methyl]-3-(4-oxopyridin-1-yl)propanamide Chemical compound C([C@@H](N)C(=O)NC[C@@H]1[C@H]([C@H](O)[C@@H](CO)N1)O)N1C=CC(=O)C=C1 MSRRUOTWMWVEQW-SYLRKERUSA-N 0.000 claims description 4
- 125000001617 2,3-dimethoxy phenyl group Chemical group [H]C1=C([H])C(*)=C(OC([H])([H])[H])C(OC([H])([H])[H])=C1[H] 0.000 claims description 4
- 125000004203 4-hydroxyphenyl group Chemical group [H]OC1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 208000020446 Cardiac disease Diseases 0.000 claims description 4
- 208000000609 Pick Disease of the Brain Diseases 0.000 claims description 4
- 208000024571 Pick disease Diseases 0.000 claims description 4
- 201000004681 Psoriasis Diseases 0.000 claims description 4
- 229940124639 Selective inhibitor Drugs 0.000 claims description 4
- 206010052779 Transplant rejections Diseases 0.000 claims description 4
- 206010047115 Vasculitis Diseases 0.000 claims description 4
- 230000007815 allergy Effects 0.000 claims description 4
- UMIVXZPTRXBADB-UHFFFAOYSA-N benzocyclobutene Chemical compound C1=CC=C2CCC2=C1 UMIVXZPTRXBADB-UHFFFAOYSA-N 0.000 claims description 4
- 230000007850 degeneration Effects 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- YLQWCDOCJODRMT-UHFFFAOYSA-N fluoren-9-one Chemical compound C1=CC=C2C(=O)C3=CC=CC=C3C2=C1 YLQWCDOCJODRMT-UHFFFAOYSA-N 0.000 claims description 4
- 208000019622 heart disease Diseases 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 230000009610 hypersensitivity Effects 0.000 claims description 4
- FGEDNSYCTZZBMJ-KBUPBQIOSA-N methyl 2-[[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]methylcarbamoyl]-1h-indole-5-carboxylate Chemical compound C=1C2=CC(C(=O)OC)=CC=C2NC=1C(=O)NC[C@H]1N[C@H](CO)[C@@H](O)[C@@H]1O FGEDNSYCTZZBMJ-KBUPBQIOSA-N 0.000 claims description 4
- 208000032207 progressive 1 supranuclear palsy Diseases 0.000 claims description 4
- 230000001105 regulatory effect Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims description 4
- 238000009825 accumulation Methods 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000000750 progressive effect Effects 0.000 claims description 3
- MUHANULUVVIESX-ZYUZMQFOSA-N (2r,3r,4r,5r)-2-(azidomethyl)-1-butyl-5-(hydroxymethyl)pyrrolidine-3,4-diol Chemical compound CCCCN1[C@H](CO)[C@@H](O)[C@H](O)[C@H]1CN=[N+]=[N-] MUHANULUVVIESX-ZYUZMQFOSA-N 0.000 claims description 2
- DVNILBJZYYQOMN-KVTDHHQDSA-N (2r,3r,4r,5r)-2-(azidomethyl)-5-(hydroxymethyl)pyrrolidine-3,4-diol Chemical compound OC[C@H]1N[C@H](CN=[N+]=[N-])[C@@H](O)[C@@H]1O DVNILBJZYYQOMN-KVTDHHQDSA-N 0.000 claims description 2
- OQEBIHBLFRADNM-UHFFFAOYSA-N 1,4-dideoxy-1,4-imino-d-ribitol Chemical compound OCC1NCC(O)C1O OQEBIHBLFRADNM-UHFFFAOYSA-N 0.000 claims description 2
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000006275 3-bromophenyl group Chemical group [H]C1=C([H])C(Br)=C([H])C(*)=C1[H] 0.000 claims description 2
- PSZMEYLKWNOGJG-ZYUZMQFOSA-N 5-[[[(2r,3r,4r,5r)-3,4-dihydroxy-5-(hydroxymethyl)pyrrolidin-2-yl]methylamino]methylidene]-1,3-dimethyl-1,3-diazinane-2,4,6-trione Chemical compound O=C1N(C)C(=O)N(C)C(=O)C1=CNC[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)N1 PSZMEYLKWNOGJG-ZYUZMQFOSA-N 0.000 claims description 2
- 208000023697 ABri amyloidosis Diseases 0.000 claims description 2
- 208000017227 ADan amyloidosis Diseases 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 206010002198 Anaphylactic reaction Diseases 0.000 claims description 2
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 206010003645 Atopy Diseases 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000004434 Calcinosis Diseases 0.000 claims description 2
- 208000033647 Classic progressive supranuclear palsy syndrome Diseases 0.000 claims description 2
- 208000028698 Cognitive impairment Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000011231 Crohn disease Diseases 0.000 claims description 2
- 206010012442 Dermatitis contact Diseases 0.000 claims description 2
- 201000010374 Down Syndrome Diseases 0.000 claims description 2
- 206010013700 Drug hypersensitivity Diseases 0.000 claims description 2
- 206010014954 Eosinophilic fasciitis Diseases 0.000 claims description 2
- 206010018341 Gliosis Diseases 0.000 claims description 2
- 206010018364 Glomerulonephritis Diseases 0.000 claims description 2
- 208000009329 Graft vs Host Disease Diseases 0.000 claims description 2
- 208000030836 Hashimoto thyroiditis Diseases 0.000 claims description 2
- 206010019315 Heart transplant rejection Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000001953 Hypotension Diseases 0.000 claims description 2
- 201000000162 ITM2B-related cerebral amyloid angiopathy 1 Diseases 0.000 claims description 2
- 201000000194 ITM2B-related cerebral amyloid angiopathy 2 Diseases 0.000 claims description 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 2
- 208000006877 Insect Bites and Stings Diseases 0.000 claims description 2
- 206010023439 Kidney transplant rejection Diseases 0.000 claims description 2
- 206010024715 Liver transplant rejection Diseases 0.000 claims description 2
- 208000019693 Lung disease Diseases 0.000 claims description 2
- 206010051604 Lung transplant rejection Diseases 0.000 claims description 2
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 2
- 206010068871 Myotonic dystrophy Diseases 0.000 claims description 2
- 206010028851 Necrosis Diseases 0.000 claims description 2
- 208000014060 Niemann-Pick disease Diseases 0.000 claims description 2
- 206010049169 Pancreas transplant rejection Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 206010035664 Pneumonia Diseases 0.000 claims description 2
- 208000024777 Prion disease Diseases 0.000 claims description 2
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 2
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 2
- 206010039085 Rhinitis allergic Diseases 0.000 claims description 2
- 206010039710 Scleroderma Diseases 0.000 claims description 2
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 2
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 claims description 2
- 208000006045 Spondylarthropathies Diseases 0.000 claims description 2
- 208000037065 Subacute sclerosing leukoencephalitis Diseases 0.000 claims description 2
- 206010042297 Subacute sclerosing panencephalitis Diseases 0.000 claims description 2
- 201000009594 Systemic Scleroderma Diseases 0.000 claims description 2
- 206010042953 Systemic sclerosis Diseases 0.000 claims description 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 2
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000024780 Urticaria Diseases 0.000 claims description 2
- 208000018756 Variant Creutzfeldt-Jakob disease Diseases 0.000 claims description 2
- 208000002029 allergic contact dermatitis Diseases 0.000 claims description 2
- 201000010105 allergic rhinitis Diseases 0.000 claims description 2
- 208000003455 anaphylaxis Diseases 0.000 claims description 2
- 238000002399 angioplasty Methods 0.000 claims description 2
- 125000005018 aryl alkenyl group Chemical group 0.000 claims description 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 2
- 125000005015 aryl alkynyl group Chemical group 0.000 claims description 2
- 125000003118 aryl group Chemical group 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 201000009564 autosomal recessive limb-girdle muscular dystrophy type 2A Diseases 0.000 claims description 2
- 210000004227 basal ganglia Anatomy 0.000 claims description 2
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 claims description 2
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 claims description 2
- 230000000740 bleeding effect Effects 0.000 claims description 2
- 229910052796 boron Inorganic materials 0.000 claims description 2
- 210000004556 brain Anatomy 0.000 claims description 2
- 229910052794 bromium Inorganic materials 0.000 claims description 2
- 230000002308 calcification Effects 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 229910052801 chlorine Inorganic materials 0.000 claims description 2
- 238000003776 cleavage reaction Methods 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 208000017004 dementia pugilistica Diseases 0.000 claims description 2
- 201000001981 dermatomyositis Diseases 0.000 claims description 2
- 125000004915 dibutylamino group Chemical group C(CCC)N(CCCC)* 0.000 claims description 2
- 201000005311 drug allergy Diseases 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 206010014599 encephalitis Diseases 0.000 claims description 2
- 201000009580 eosinophilic pneumonia Diseases 0.000 claims description 2
- 206010015037 epilepsy Diseases 0.000 claims description 2
- 230000020764 fibrinolysis Effects 0.000 claims description 2
- 229910052731 fluorine Inorganic materials 0.000 claims description 2
- 230000007387 gliosis Effects 0.000 claims description 2
- 208000024908 graft versus host disease Diseases 0.000 claims description 2
- 125000001072 heteroaryl group Chemical group 0.000 claims description 2
- 125000004447 heteroarylalkenyl group Chemical group 0.000 claims description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims description 2
- 208000021822 hypotensive Diseases 0.000 claims description 2
- 230000001077 hypotensive effect Effects 0.000 claims description 2
- 208000027866 inflammatory disease Diseases 0.000 claims description 2
- 206010022437 insomnia Diseases 0.000 claims description 2
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims description 2
- 229910052740 iodine Inorganic materials 0.000 claims description 2
- 229910052742 iron Inorganic materials 0.000 claims description 2
- 208000028867 ischemia Diseases 0.000 claims description 2
- 210000003734 kidney Anatomy 0.000 claims description 2
- 231100000518 lethal Toxicity 0.000 claims description 2
- 230000001665 lethal effect Effects 0.000 claims description 2
- 210000004072 lung Anatomy 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 206010028417 myasthenia gravis Diseases 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 230000017074 necrotic cell death Effects 0.000 claims description 2
- 210000002682 neurofibrillary tangle Anatomy 0.000 claims description 2
- 230000000324 neuroprotective effect Effects 0.000 claims description 2
- 229910052757 nitrogen Inorganic materials 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 229910052698 phosphorus Inorganic materials 0.000 claims description 2
- 208000005987 polymyositis Diseases 0.000 claims description 2
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims description 2
- 230000007017 scission Effects 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 230000035939 shock Effects 0.000 claims description 2
- 239000007787 solid Substances 0.000 claims description 2
- 201000005671 spondyloarthropathy Diseases 0.000 claims description 2
- 229910052717 sulfur Inorganic materials 0.000 claims description 2
- 238000001356 surgical procedure Methods 0.000 claims description 2
- 230000005951 type IV hypersensitivity Effects 0.000 claims description 2
- 208000027930 type IV hypersensitivity disease Diseases 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 17
- 208000037658 Parkinson-dementia complex of Guam Diseases 0.000 claims 1
- 206010048327 Supranuclear palsy Diseases 0.000 claims 1
- 210000000349 chromosome Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000007812 deficiency Effects 0.000 description 2
- 102000005744 Glycoside Hydrolases Human genes 0.000 description 1
- 108010031186 Glycoside Hydrolases Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000035802 chromosome 17 disease Diseases 0.000 description 1
- 230000019771 cognition Effects 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9747008P | 2008-09-16 | 2008-09-16 | |
| US61/097,470 | 2008-09-16 | ||
| PCT/CA2009/001302 WO2010037207A1 (en) | 2008-09-16 | 2009-09-16 | Selective glycosidase inhibitors and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012502884A JP2012502884A (ja) | 2012-02-02 |
| JP2012502884A5 true JP2012502884A5 (enExample) | 2012-07-12 |
Family
ID=42072983
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011526360A Pending JP2012502884A (ja) | 2008-09-16 | 2009-09-16 | 選択的グリコシダーゼ阻害剤およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110301217A1 (enExample) |
| EP (1) | EP2344452A4 (enExample) |
| JP (1) | JP2012502884A (enExample) |
| AU (1) | AU2009299073B2 (enExample) |
| CA (1) | CA2737267A1 (enExample) |
| WO (1) | WO2010037207A1 (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2436687A1 (en) * | 2005-03-01 | 2012-04-04 | Simon Fraser University | Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
| US8334310B2 (en) | 2006-08-31 | 2012-12-18 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| WO2010012107A1 (en) * | 2008-08-01 | 2010-02-04 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| EP2569291B1 (en) | 2010-05-11 | 2016-04-06 | Simon Fraser University | Selective glycosidase inhibitors and uses thereof |
| CA2813493C (en) * | 2010-10-11 | 2019-07-09 | University Of Zurich | Human anti-tau antibodies |
| TW201249848A (en) | 2010-11-08 | 2012-12-16 | Merck Sharp & Dohme | Selective glycosidase inhibitors and uses thereof |
| US8901087B2 (en) | 2010-11-08 | 2014-12-02 | Merck Sharp & Dohme Corp. | Selective glycosidase inhibitors and uses thereof |
| WO2012061927A1 (en) | 2010-11-08 | 2012-05-18 | Alectos Therapeutics, Inc. | Selective glycosidase inhibitors and uses thereof |
| MX343822B (es) | 2010-12-23 | 2016-11-24 | Merck Sharp & Dohme | Inhibidores selectivos de glucosidasas, y usos de los mismos. |
| GB201103526D0 (en) * | 2011-03-02 | 2011-04-13 | Summit Corp Plc | Selective glycosidase inhibitors and uses thereof |
| WO2012126091A1 (en) | 2011-03-24 | 2012-09-27 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US9718854B2 (en) | 2011-03-31 | 2017-08-01 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| EP2726492B1 (en) | 2011-06-27 | 2017-11-01 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| US9199949B2 (en) | 2011-06-27 | 2015-12-01 | Alectos Therapeutics Inc. | Selective glycosidase inhibitors and uses thereof |
| JP6147737B2 (ja) | 2011-06-27 | 2017-06-14 | アレクトス・セラピューティクス・インコーポレイテッド | 選択的グリコシダーゼ阻害剤およびその使用 |
| BR112014027724B1 (pt) | 2012-05-08 | 2022-05-03 | Merck Sharp & Dohme Corp. E Alectos Therapeutics Inc | Composto, e, composição farmacêutica |
| WO2014032188A1 (en) * | 2012-08-31 | 2014-03-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| WO2014032185A1 (en) | 2012-08-31 | 2014-03-06 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| CA2890115A1 (en) | 2012-10-31 | 2014-05-08 | Alectos Therapeutics Inc. | Glycosidase inhibitors and uses thereof |
| WO2024083820A1 (en) | 2022-10-18 | 2024-04-25 | Institut National de la Santé et de la Recherche Médicale | Method and composition for determining the level of o-glcnacylation in horses |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8900719D0 (en) * | 1989-01-13 | 1989-03-08 | Nycomed As | Compounds |
| US5451679A (en) * | 1994-03-08 | 1995-09-19 | G. D. Searle & Co. | 2-chloro and 2-bromo derivatives of 1,5-iminosugars |
| FR2817472B1 (fr) * | 2000-12-06 | 2003-01-03 | Oreal | Composition de teinture d'oxydation a base de 1-(4-aminophenyl)pyrrolidines substituees au moins en position 2 et 3 et procede de teinture de mise en oeuvre |
| JP4363183B2 (ja) * | 2001-06-08 | 2009-11-11 | 三菱化学株式会社 | アザ糖化合物 |
| EP1713485A4 (en) * | 2004-01-20 | 2007-09-19 | Optimer Pharmaceuticals Inc | TREATMENT OF DEGENERATIVE TREATMENTS IN A MAMMALIAN WITH GLYCOSIDASE INHIBITORS |
| EP2436687A1 (en) * | 2005-03-01 | 2012-04-04 | Simon Fraser University | Selective glycosidase inhibitors, methods of making inhibitors, and uses thereof |
| US7919521B2 (en) * | 2005-12-05 | 2011-04-05 | Academia Sinica | Five-membered iminocyclitol derivatives as selective and potent glycosidase inhibitors: new structures for antivirals and osteoarthritis therapeutics |
-
2009
- 2009-09-16 AU AU2009299073A patent/AU2009299073B2/en not_active Ceased
- 2009-09-16 EP EP20090817127 patent/EP2344452A4/en not_active Withdrawn
- 2009-09-16 CA CA2737267A patent/CA2737267A1/en not_active Abandoned
- 2009-09-16 JP JP2011526360A patent/JP2012502884A/ja active Pending
- 2009-09-16 US US13/119,362 patent/US20110301217A1/en not_active Abandoned
- 2009-09-16 WO PCT/CA2009/001302 patent/WO2010037207A1/en not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012502884A5 (enExample) | ||
| JP2014524911A5 (enExample) | ||
| JP2014501740A5 (enExample) | ||
| JP2015534991A5 (enExample) | ||
| JP2011529858A5 (enExample) | ||
| JP2011529857A5 (enExample) | ||
| WO2008025170B1 (en) | Selective glycosidase inhibitors and uses thereof | |
| RU2013134345A (ru) | Селективные ингибиторы гликозидазы и их применение | |
| JP6243472B2 (ja) | カゼインキナーゼ１デルタ（ｃｋ１デルタ）阻害剤 | |
| Kikuchi et al. | Potent antimalarial febrifugine analogues against the plasmodium malaria parasite | |
| RU2757218C2 (ru) | Аминопиразолы в качестве селективных ингибиторов янус-киназы | |
| Zhi et al. | Hybrid antibacterials. DNA polymerase− topoisomerase inhibitors | |
| Patel et al. | Synthesis of potential antitubercular and antimicrobial s-triazine-based scaffolds via Suzuki cross-coupling reaction | |
| JP2013541596A5 (enExample) | ||
| WO2003076437A1 (de) | Cdk inhibitorische 2-heteroaryl-pyrimidine, deren herstellung und verwendung als arzneimittel | |
| JP5250553B2 (ja) | ２−置換―６−ヘテロ環ピリミドン誘導体 | |
| RU2014102232A (ru) | Селективные ингибиторы гликозидазы и их применение | |
| RU2015120556A (ru) | Ингибиторы гликозидаз и их применения | |
| JP2016512515A5 (enExample) | ||
| JP2004505973A (ja) | ブラジキニンアンタゴニストとしての１，４−ジヒドロピリジン類 | |
| CA2545092A1 (en) | Quinolonecarboxylic acid compounds having 5-ht4 receptor agonistic activity | |
| Patel et al. | A new class of 2-(4-cyanophenyl amino)-4-(6-bromo-4-quinolinyloxy)-6-piperazinyl (piperidinyl)-1, 3, 5-triazine analogues with antimicrobial/antimycobacterial activity | |
| JP2015506993A (ja) | グリコーゲンシンターゼキナーゼ３ベータ阻害剤としての１ｈ−インダゾール−３−カルボキサミド化合物 | |
| Desai et al. | Synthesis, characterization and antimicrobial screening of thiazole based 1, 3, 4-oxadiazoles heterocycles | |
| MX2011000402A (es) | Derivado de pirimidil sulfonamida y su uso para el tratamiento de enfermedades mediadas por quimiocinas. |